The FDA’s approval of Blujepa, the first new antibiotic for urinary tract infections (UTIs) in nearly 30 years, is a significant development in the fight against drug-resistant bacteria. This class of antibiotics, known as triazaacenaphthylenes, targets two key enzymes that E. coli bacteria need to replicate and survive. The approval comes at a crucial time when more than 2.8 million antimicrobial-resistant infections occur annually in the U.S., according to the Centers for Disease Control and Prevention (CDC). A 2019 study found resistance to at least one drug in over 92% of bacteria that can cause UTIs, with around 80% showing resistance to at least two drugs. The development of new antibiotics like Blujepa is crucial for reducing the risk of drug-resistant infections and maintaining effective treatment options. Dr. Candace Granberg, a pediatric urologist and surgeon-in-chief at Mayo Clinic Children’s in Rochester, Minnesota, emphasizes that “we absolutely need new antibiotics for uncomplicated UTIs.” The approval of Blujepa highlights the importance of continued research and development to combat drug resistance and ensure effective treatment options remain available.
[Original Article](https://www.nbcnews.com/health/health-news/fda-approves-first-new-antibiotic-utis-nearly-30-years-rcna197953) #approves #first [Visit GhostAI](https://ghostai.pro/)
[Join our Discord](https://discord.com/invite/zgKZUJ6V8z)